The role of ocular blood flow in OAG

Article

Ocular blood flow alterations and previous visual field damage may play an important role in visual field progression in open angle glaucoma (OAG), according to Antonio Martinez and colleagues from the Instituto Gallego de Oftalmologia, Spain.

Ocular blood flow alterations and previous visual field damage may play an important role in visual field progression in open angle glaucoma (OAG), according to Antonio Martinez and colleagues from the Instituto Gallego de Oftalmologia, Spain.

All OAG patients recruited or referred to one centre between January and July 2001 were examined. Kaplan-Meier survival analysis was used to estimate visual field progression and variables considered to be possible risk factors were evaluated using the one-way analysis of variance (ANOVA) and Cox proportional hazards regression analysis.

A total of 40 patients were evaluated during the trial period. Mean time to progression was 37.88 months, 95% confidence interval 33.10-42.65. Sixteen patients (40%) showed visual field progression. Significant risk factors included pattern standard deviation, end-diastolic velocity in the ophthalmic artery and resistance index in the ophthalmic artery.

The results suggest that ocular blood flow alterations may play a central role in the visual field progression in OAG patients.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.